Robert's Feed
May 21, 2015
via Breakingviews

CVS-Omnicare portends lower doses of pharmacy M&A

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

CVS Health’s $10 billion deal for Omnicare portends lower doses of pharmacy M&A. The drugstore’s purchase gives it entrance to nursing homes and expands specialty medicine distribution. But the increasingly concentrated industry is bumping up against antitrust concerns and may have to live with fewer transactions.

May 21, 2015
via Breakingviews

CVS-Omnicare portends lower doses of pharmacy M&A

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

CVS Health’s $10 billion deal for Omnicare portends lower doses of pharmacy M&A. The drugstore’s purchase gives it entrance to nursing homes and expands specialty medicine distribution. But the increasingly concentrated industry is bumping up against antitrust concerns and may have to live with fewer transactions.

May 18, 2015
via Breakingviews

TPG’s $8 bln drug sale far from generic

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The latest off-patent drug deal is far from generic. With the $8 billion sale of Par Pharmaceutical, buyout firm TPG will generate an outsized return on its investment in three years. Though it’s a rare development, the eagerness of buyers like Endo International means more sellers are bound to benefit.

May 18, 2015
via Breakingviews

TPG’s $8 bln drug sale far from generic

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The latest off-patent drug deal is far from generic. With the $8 billion sale of Par Pharmaceutical, buyout firm TPG will generate an outsized return on its investment in three years. Though it’s a rare development, the eagerness of buyers like Endo International means more sellers are bound to benefit.

May 12, 2015
via Breakingviews

Verizon’s dumb pipes no smarter with $4.4 bln AOL

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Verizon’s dumb pipes become no smarter by running $4.4 billion AOL through them. Seeking refuge from a vicious wireless war, the U.S. telecom carrier is buying the custodian of the Huffington Post and old internet dial-up customers. AOL’s video ad tech business may be the ostensible prize, but it faces many threats. This is just another silly deal involving a company best known for its involvement in a catastrophic one.

May 12, 2015
via Breakingviews

Verizon’s dumb pipes no smarter with $4.4 bln AOL

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Verizon’s dumb pipes become no smarter by running $4.4 billion AOL through them. Seeking refuge from a vicious wireless war, the U.S. telecom carrier is buying the custodian of the Huffington Post and old internet dial-up customers. AOL’s video ad tech business may be the ostensible prize, but it faces many threats. This is just another silly deal involving a company best known for its involvement in a catastrophic one.

May 6, 2015
via Breakingviews

Alexion puts high stock to good use in biotech bid

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Alexion Pharmaceuticals is putting its high-flying stock to good use. The drugmaker’s $8.4 billion offer for rival Synageva BioPharma includes an astonishing 136 percent premium. The stonking price is based on the rare disease specialist’s view that investors underestimate its target’s value. Exchanging a chunk of pricey paper for those assets may be a savvy move.

May 6, 2015
via Breakingviews

Alexion puts high stock to good use in biotech bid

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Alexion Pharmaceuticals is putting its high-flying stock to good use. The drugmaker’s $8.4 billion offer for rival Synageva BioPharma includes an astonishing 136 percent premium. The stonking price is based on the rare disease specialist’s view that investors underestimate its target’s value. Exchanging a chunk of pricey paper for those assets may be a savvy move.

May 6, 2015
via Breakingviews

Would Microsoft really want to own Salesforce?

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Would Microsoft really want to own Salesforce.com? Buying the cloud-based, customer-service software maker could make businesses less likely to ditch Office. It might, however, cost Microsoft about $60 billion, a greater sum than it has spent on all its previous deals combined. A bold bet for boss Satya Nadella would create earnings dilution that irritates his shareholders.

May 6, 2015
via Breakingviews

Would Microsoft really want to own Salesforce?

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Would Microsoft really want to own Salesforce.com? Buying the cloud-based, customer-service software maker could make businesses less likely to ditch Office. It might, however, cost Microsoft about $60 billion, a greater sum than it has spent on all its previous deals combined. A bold bet for boss Satya Nadella would create earnings dilution that irritates his shareholders.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert